

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-Q

(Mark One)

**QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934**

For the quarterly period ended March 31, 2016.

**TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934**

For the transition period from _____ to _____.

Commission File Number: 333-176954



ENDONOVO THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction of
incorporation or organization)

45-2552528
(I.R.S. Employer
Identification No.)

6320 Canoga Avenue, 15th Floor, Woodland Hills, CA 91367
(Address of principal executive offices, zip code)

(800) 489-4774
(Registrant's telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer

Accelerated filer

Non-accelerated filer
(do not check if smaller reporting company)

Smaller reporting company

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No

As of May 20, 2016, there were 109,616,075 shares of common stock, \$0.0001 par value issued and outstanding.

ENDONOVO THERAPEUTICS, INC.
TABLE OF CONTENTS
FORM 10-Q REPORT
March 31, 2016

	Page Number
PART I - FINANCIAL INFORMATION	
Item 1. Financial Statements.	4
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations.	14
Item 3. Quantitative and Qualitative Disclosures About Market Risk.	18
Item 4. Controls and Procedures.	18
PART II - OTHER INFORMATION	
Item 1. Legal Proceedings.	19
Item 1A. Risk Factors.	19
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.	19
Item 3. Defaults Upon Senior Securities.	20
Item 4. Mine Safety Disclosures	20
Item 5. Other Information.	20
Item 6. Exhibits.	20
SIGNATURES	21

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements.

Endonovo Therapeutics, Inc. and Subsidiaries
Condensed Consolidated Balance Sheets

	March 31, 2016 (Unaudited)	December 31, 2015 (Audited)
ASSETS		
Current assets:		
Cash	\$ 108,893	\$ 41,473
Other current assets	137,420	336,233
Total current assets	246,313	377,706
Property, Plant and Equipment, net	27,699	31,657
	\$ 274,012	\$ 409,363
LIABILITIES AND SHAREHOLDERS' DEFICIT		
Current Liabilities		
Accounts payable and accrued expenses	\$ 4,222,997	\$ 3,990,185
Short term advances, related parties	-	3,605
Notes payable, net of discounts of \$149,775 as of March 31, 2016 and \$321,961 as of December 31, 2015	1,178,975	1,261,790
Notes payable - related parties	245,000	245,000
Derivative liability	3,340,633	3,973,542
Current portion of long term loan	12,121	12,031
Total current liabilities	8,999,726	9,486,153
Notes payable, net of discounts of \$693,390 as of March 31, 2016 and \$477,346 of December 31, 2015	119,110	27,654
Long term loan	13,552	16,616
Acquisition payable	155,000	155,000
Total liabilities	9,287,388	9,685,423
COMMITMENTS AND CONTINGENCIES		
Shareholders' deficit		
Super AA super voting preferred stock, \$0.0001 par value; 1,000,000 authorized and 1,000 issued and outstanding	-	-
Common stock, \$.0001 par value; 250,000,000 shares authorized; 108,289,265 and 104,803,401 shares issued and outstanding as of March 31, 2016 and December 31, 2015	10,830	10,479
Additional paid-in capital	4,939,438	3,773,642
Stock subscriptions	(1,570)	(1,570)
Accumulated deficit	(13,962,074)	(13,058,611)
Total shareholders' deficit	(9,013,376)	(9,276,060)
	\$ 274,012	\$ 409,363

See accompanying summary of accounting policies and notes to unaudited condensed consolidated financial statements.

Endonovo Therapeutics, Inc. and Subsidiaries
Condensed Consolidated Statement of Operations
(Unaudited)

	Three Months Ended	
	March 31,	
	2016	2015
Revenues, net	\$ -	\$ 2,745
Cost of goods sold	-	824
Gross profit	-	1,921
Operating expenses	1,402,120	433,554
Loss from operations	(1,402,120)	(431,633)
Other income (expense)		
Change in fair value of derivative liability	1,024,602	-
Gain on extinguishment of debt	133,038	-
Interest expense, net	(658,983)	(48,522)
	498,657	(48,522)
Loss before income taxes	(903,463)	(480,155)
Provision for income taxes	-	-
Net loss	\$ (903,463)	\$ (480,155)
Basic and diluted loss per share	\$ (0.01)	\$ (0.01)
Weighted average common share outstanding:		
Basic and diluted	106,567,261	84,824,577

See accompanying summary of accounting policies and notes to unaudited condensed consolidated financial statements.

Endonovo Therapeutics, Inc. and Subsidiaries
Condensed Consolidated Statement of Cash Flows
(Unaudited)

	Three Months ended March 31,	
	2016	2015
Operating activities:		
Net loss	\$ (903,463)	\$ (480,155)
Adjustments to reconcile net loss to cash used in operating activities:		
Depreciation and amortization expense	3,958	3,640
Fair value of equity issued for services	518,457	2,304
Non-cash amortization of interest	529,456	1,766
Non-cash expenses paid in debt issuance	115,000	-
Change in fair value of derivative liability	(1,024,602)	-
Gain on extinguishment of liabilities	(133,038)	-
Changes in assets and liabilities:		
Other current assets	200,000	2,000
Accounts payable and accrued expenses	269,363	276,609
Net cash used in operating activities	<u>(424,869)</u>	<u>(193,836)</u>
Investing activities:		
Net cash used in investing activities	<u>-</u>	<u>-</u>
Financing activities:		
Proceeds from the issuance of notes payable	285,000	212,500
Proceeds from related party short-term advances	5,508	7,755
Proceeds from issuance of common stock	366,275	177
Repayments on notes payable	(125,000)	-
Repayment of prepayment premium on note payable	(26,220)	-
Repayments on related parties short term advances	(10,300)	-
Payment against long term loan	(2,974)	(1,936)
Net cash provided by financing activities	<u>492,289</u>	<u>218,496</u>
Net increase in cash	67,420	24,660
Cash, beginning of year	41,473	988
Cash, end of period	<u>\$ 108,893</u>	<u>\$ 25,648</u>
Supplemental disclosure of cash flow information:		
Cash paid for interest	\$ 12,383	\$ -
Cash paid for income taxes	<u>\$ -</u>	<u>\$ -</u>
Non Cash Investing and Financing Activities:		
Conversion of notes payable and accrued interest to equity	<u>\$ 269,416</u>	<u>\$ 328,138</u>

See accompanying summary of accounting policies and notes to unaudited condensed consolidated financial statements.

Endonovo Therapeutics, Inc. and Subsidiaries
Condensed Consolidated Statement of Shareholders' Deficit
(Unaudited)

	Series AA Preferred Stock		Common Stock		Additional	Common Stock	Retained Earnings	Total
	Shares	Amount	Shares	Amount	Paid-in Capital	Subscription Receivable		Shareholder's Deficit
Balance December 31, 2015	1,000	\$ -	104,803,401	\$ 10,479	\$ 3,773,642	\$ (1,570)	\$ (13,058,611)	\$ (9,276,060)
Shares issued for cash	-	-	512,273	51	106,973	-	-	107,024
Private placement units issued for cash	-	-	975,827	98	271,152	-	-	271,250
Shares issued for services	-	-	1,051,504	106	492,700	-	-	492,806
Shares issued with notes payable and extensions	-	-	70,110	8	25,643	-	-	25,651
Private placement units issued for conversion of notes payable and accrued interest	-	-	876,150	88	269,328	-	-	269,416
Net loss for the period ended March 31, 2016	-	-	-	-	-	-	(903,463)	(903,463)
Balance March 31, 2016	1,000	\$ -	108,289,265	\$ 10,830	\$ 4,939,438	\$ (1,570)	\$ (13,962,074)	\$ (9,013,376)

See accompanying summary of accounting policies and notes to unaudited condensed consolidated financial statements.

Endonovo Therapeutics, Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements

Note 1 - Organization and Nature of Business

Endonovo Therapeutics, Inc. and Subsidiaries (the “Company” or “ETI”) is primarily focused in the business of biomedical research and development, particularly in regenerative medicine, which has included the development of its proprietary square wave form device. The Company has historically been involved with intellectual property licensing and commercialization.

Basis of Presentation and Principles of Consolidation

The accompanying unaudited interim condensed consolidated financial statements have been presented in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and the instructions to Article 8 of Regulation S-X. Accordingly, the financial statements do not include all of the information and notes required by GAAP for complete financial statements. The condensed consolidated financial statements as of March 31, 2016 and 2015 are unaudited; however, in the opinion of management such interim condensed consolidated financial statements reflect all adjustments, consisting solely of normal recurring adjustments, necessary for a fair presentation of the results for the periods presented. The results of operations for the period presented are not necessarily indicative of the results that might be expected for future interim periods or for the full year.

The consolidated financial statements of the Company include the accounts of ETI and IPR as of March 14, 2012; Aviva as of April 2, 2013; and WeHealAnimals as of November 16, 2013. All significant intercompany accounts and transactions are eliminated in consolidation.

Going Concern

These accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business for a period following the date of these consolidated financial statements. The Company has raised approximately \$650,000 in debt and equity financing for the period January 1, 2016 to March 31, 2016. The Company is raising additional capital through debt and equity securities in order to continue the funding of its operations. However, there is no assurance that the Company can raise enough funds or generate sufficient revenues to pay its obligations as they become due, which raises substantial doubt about our ability to continue as a going concern. No adjustments have been made to the carrying value of assets or liabilities as a result of this uncertainty. To reduce the risk of not being able to continue as a going concern, management and has initiated a private placement offering to raise capital through the sale of its common stock and is seeking out profitable companies. Although, uncertainty exists as to whether the Company will be able to generate enough cash from operations to fund the Company’s working capital needs or raise sufficient capital to meet the Company’s obligations as they become due, no adjustments have been made to the carrying value of assets or liabilities as a result of this uncertainty.

Net Income (Loss) per Share

For the three month period ending March 31, 2016, the Company had 7,747,422 of weighted average common shares relating to the convertible debt, under the if-converted method, however, these shares are not dilutive because the Company recorded a loss during the fiscal quarter. For the three months ended March 31, 2015, the Company had no dilutive securities.

Recent Accounting Standard Updates

The Company is not aware of any recently issued accounting pronouncements that when adopted will have a material effect on the Company’s financial position or results of its operations.

Endonovo Therapeutics, Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements (continued)

Note 2 – Property, Plant and Equipment

The following is a summary of equipment, at cost, less accumulated depreciation at March 31, 2016 and December 31, 2015:

	March 31, 2016	December 31, 2015
Autos	\$ 64,458	\$ 64,458
Medical equipment	5,000	5,000
Other equipment	8,774	8,774
	<u>78,232</u>	<u>78,232</u>
Less accumulated depreciation	50,533	46,575
	<u>\$ 27,699</u>	<u>\$ 31,657</u>

Note 3 - Notes Payable and Long Term Loan

Notes Payable

During the three months ended March 31, 2016, the Company issued a Convertible Note (“Variable Note”) with an original term of one year and nine months and an add-on interest equal to 10% of the initial principal which contains a variable conversion rate with a discount of 30% of the Company’s common stock based on the terms included in the Variable Note. The Variable Note contains a prepayment option which enables the Company to prepay the note for a period of 0-180 days subsequent to issuance at a premium of 125%. The gross amount of this Variable Note outstanding is \$302,500 as of March 31, 2016.

	March 31, 2016	December 31, 2015
Notes payable at beginning of period	\$ 2,333,751	\$ 1,377,416
Notes payable issued	302,500	1,586,250
Repayments of notes payable in cash	(125,000)	(138,000)
Less amounts converted to equity	(125,000)	(491,915)
Notes payable at end of period	<u>2,386,251</u>	<u>2,333,751</u>
Less debt discount	(843,164)	(799,307)
	<u>\$ 1,543,087</u>	<u>\$ 1,534,444</u>
Notes payable issued to related parties	<u>\$ 245,000</u>	<u>\$ 245,000</u>
Notes payable issued to non-related parties	<u>\$ 1,298,087</u>	<u>\$ 1,289,444</u>

Endonovo Therapeutics, Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements (continued)

The maturity dates on the notes payable are as follows:

12 months ending,	Notes to		Total
	Related parties	Non-related parties	
March 31, 2017	\$ 245,000	\$ 1,328,750	\$ 1,573,750
March 31, 2018	\$ -	\$ 762,500	\$ 762,500
March 31, 2019	\$ -	\$ 50,000	\$ 50,000
	<u>\$ 245,000</u>	<u>\$ 2,141,250</u>	<u>\$ 2,386,250</u>
Current notes payable	\$ 245,000	\$ 1,328,750	\$ 1,573,750
Long term notes payable	\$ -	\$ 812,500	\$ 812,500

Derivative Liability

The Company has issued Variable Debentures which contained variable conversion rates based on unknown future prices of the Company's common stock. This results in a conversion feature. The Company measures the conversion feature using the Black-Scholes option valuation model using the following assumptions:

	Three months ended March 31,	
	2016	2015
Expected term	3 to 28 months	0
Exercise price	\$0.07 to \$0.26	\$0.00
Expected volatility	221% to 264%	0%
Expected dividends	0	0
Risk-free interest rate	0.59% to 1.06%	0.00%
Forfeitures	0	0

The time period over which the Company will be required to evaluate the fair value of the conversion feature is nine to twenty-four months or conversion.

The assumptions used in determining fair value represent management's best estimates, but these estimates involve inherent uncertainties and the application of management's judgment. As a result, if factors change, including changes in the market value of the Company's common stock, managements' assessment or significant fluctuations in the volatility of the trading market for the Company's common stock, the Company's fair value estimates could be materially different in the future.

Endonovo Therapeutics, Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements (continued)

The Company computes the fair value of the derivative liability at each reporting period and the change in the fair value is recorded as non-cash expense or non-cash income. The key component in the value of the derivative liability is the Company's stock price, which is subject to significant fluctuation and is not under its control. The resulting effect on net loss is therefore subject to significant fluctuation and will continue to be so until the Company's Variable Debentures, which the convertible feature is associated with, are converted into common stock or paid in full with cash. Assuming all other fair value inputs remain constant, the Company will record non-cash expense when its stock price increases and non-cash income when its stock price decreases.

As of March 31, 2016 and December 31, 2015, the balances of the Derivative Liability are as follows:

	Derivative Liability
Balance December 31, 2015	\$ 3,973,542
Issuance of convertible debt	628,132
Settlements by debt extinguishment	(236,439)
Change in estimated fair value	<u>(1,024,602)</u>
Balance March 31, 2016	<u>\$ 3,340,633</u>

Long Term Loan

The Company has financed the purchase of an automobile. The maturity dates on the loan are as follows:

Maturity dates of long term debt

Twelve months ending,	
March 31, 2017	\$ 12,121
March 31, 2018	\$ 12,488
March 31, 2019	<u>\$ 1,064</u>
	<u>\$ 25,673</u>
Current portion	<u>\$ 12,121</u>
Long term portion	<u>\$ 13,552</u>

Endonovo Therapeutics, Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements (continued)

Note 4 - Shareholders' Deficit

Common Stock

The Company has entered into consulting agreements with various consultants for service to be provided to the Company. The agreements stipulate a monthly fee and a certain number of shares that the consultant vests in over the term of the contract. The consultant is issued a prorated number of shares of common stock at the beginning of the contract, which the consultant earns over a three-month period. At the anniversary of each quarter, the consultant is issued a new allotment of common stock during the first 3 years of engagement. In accordance with ASC 505-50 – Equity-Based Payment to Non-Employees, the common stock shares issued to the consultant are valued upon their vesting, with interim estimates of value as appropriate during the vesting period. During the three months ended March 31, 2016, the Company issued 901,504 shares of common stock with a value of \$427,306 related to these consulting agreements.

During the three months ended March 31, 2016, the Company issued 150,000 shares of common stock related to lock-up agreements valued at \$65,500 and 512,273 shares of common stock for cash in the amount of \$107,025.

During the three months ended March 31, 2016, the Company issued pursuant to a private placement offering 1,851,977 shares of common stock and the same number of warrants for cash of \$271,250 and conversion of notes and accrued interest in the amount of \$269,416.

Also, during the three months ended March 31, 2016, the Company issued 70,110 shares of common stock valued at \$25,651 related to the extension of outstanding notes.

Series AA Preferred Shares

On February 22, 2013, the Board of Directors of the Company authorized an amendment to the Company's Articles of Incorporation, as amended (the "Articles of Incorporation"), in the form of a Certificate of Designation that authorized the issuance of up to one million (1,000,000) shares of a new series of preferred stock, par value \$0.0001 per share, designated "Series AA Super Voting Preferred Stock," for which the board of directors established the rights, preferences and limitations thereof.

Each holder of outstanding shares of Series AA Super Voting Preferred Stock shall be entitled to one hundred thousand (100,000) votes for each share of Series AA Super Voting Preferred Stock held on the record date for the determination of stockholders entitled to vote at each meeting of stockholders of the Company. As of March 31, 2016, there were 1,000 shares of Series AA Preferred stock outstanding.

Note 5 – Related Party Transactions

Two officers and executives of the Company have entered into note payable agreements with the Company. The balance of notes payable from related parties at March 31, 2016 is \$245,000.

From time-to-time officers of the Company advance monies to the Company to cover costs. During the three months ended March 31, 2016, officers advanced \$5,508 of funds to the Company, and \$10,300 were repaid to the officers. The balance of short-term advances due to two officers and executives of the Company at March 31, 2016 is \$0.

Endonovo Therapeutics, Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements (continued)

Note 6 – Fair Value Measurements

Accounting guidance on fair value measurements and disclosures defines fair value, establishes a framework for measuring the fair value of assets and liabilities using a hierarchy system, and defines required disclosures. It clarifies that fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants in the market in which the reporting entity transacts business.

The Company's balance sheet contains derivative and warrant liabilities that are recorded at fair value on a recurring basis. The three-level valuation hierarchy for disclosure of fair value is as follows:

Level 1: uses quoted market prices in active markets for identical assets or liabilities.

Level 2: uses observable market-based inputs or unobservable inputs that are corroborated by market data.

Level 3: uses unobservable inputs that are not corroborated by market data.

The fair value of the Company's recorded derivative liability is determined based on unobservable inputs that are not corroborated by market data, which require a Level 3 classification. A Black-Scholes option valuation model was used to determine the fair value. The Company records derivative liability on the condensed consolidated balance sheets at fair value with changes in fair value recorded in the condensed consolidated statements of operation.

The following table presents changes in the liabilities with significant unobservable inputs (Level 3) for the three months ended March 31, 2016:

	Fair Value Measurements Using			Total
	Quoted Prices in Active Markets for Identical Assets (Level 1)	Significant Other Observable Inputs (Level 2)	Significant Unobservable Inputs (Level 3)	
As of March 31, 2016				
Derivative liability	\$ -	\$ -	\$ 3,340,633	\$ 3,340,633
Total	\$ -	\$ -	\$ 3,340,633	\$ 3,340,633

Note 7 – Subsequent Events

Subsequent to March 31, 2016, an aggregate of 750,000 shares of restricted common stock were issued as compensation to independent contractors.

Subsequent to March 31, 2016, the Company issued 540,810 shares of its restricted common stock pursuant to a Private Placement Memorandum and private offerings.

Subsequent to March 31, 2016, an aggregate of 36,000 shares of common stock were issued for leak out agreements.

As a result of these issuances the total number of shares outstanding is 109,616,075.

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

Cautionary Notice Regarding Forward Looking Statements

The information contained in Item 2 contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Actual results may materially differ from those projected in the forward-looking statements as a result of certain risks and uncertainties set forth in this report. Although management believes that the assumptions made and expectations reflected in the forward-looking statements are reasonable, there is no assurance that the underlying assumptions will, in fact, prove to be correct or that actual results will not be different from expectations expressed in this report.

This filing contains a number of forward-looking statements which reflect management's current views and expectations with respect to our business, strategies, products, future results and events, and financial performance. All statements made in this filing other than statements of historical fact, including statements addressing operating performance, events, or developments which management expects or anticipates will or may occur in the future, including statements related to distributor channels, volume growth, revenues, profitability, new products, adequacy of funds from operations, statements expressing general optimism about future operating results, and non-historical information, are forward looking statements. In particular, the words "believe," "expect," "intend," "anticipate," "estimate," "may," and variations of such words, and similar expressions identify forward-looking statements, but are not the exclusive means of identifying such statements, and their absence does not mean that the statement is not forward-looking. These forward-looking statements are subject to certain risks and uncertainties, including those discussed below. Our actual results, performance or achievements could differ materially from historical results as well as those expressed in, anticipated, or implied by these forward-looking statements. We do not undertake any obligation to revise these forward-looking statements to reflect any future events or circumstances.

Readers should not place undue reliance on these forward-looking statements, which are based on management's current expectations and projections about future events, are not guarantees of future performance, are subject to risks, uncertainties and assumptions (including those described below), and apply only as of the date of this filing. Our actual results, performance or achievements could differ materially from the results expressed in, or implied by, these forward-looking statements. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Overview

Endonovo Therapeutics, Inc. (the "Company" or "ETI") operates in two business segments: (1) intellectual property licensing and commercialization; and (2) biomedical research and development which has included development of its proprietary square wave form device.

Our present primary focus is the development, patenting and regulatory approval of our biomedical proprietary technology.

Going Concern

Our independent registered auditors included an explanatory paragraph in their opinion on our consolidated financial statements as of and for the fiscal year ended December 31, 2015 that states our ongoing losses and lack of resources causes substantial doubt about our ability to continue as a going concern.

Critical Accounting Policies and Estimates

We prepare our condensed consolidated financial statements in accordance with accounting principles generally accepted in the U.S. (U.S. GAAP). In doing so, we have to make estimates and assumptions that affect our reported amounts of assets, liabilities, revenues, and expenses, as well as related disclosure of contingent assets and liabilities. In some cases, we could reasonably have used different accounting policies and estimates. In some cases, changes in the accounting estimates are reasonably likely to occur from period to period. Accordingly, actual results could differ materially from our estimates. To the extent that there are material differences between these estimates and actual results, our financial condition or results of operations will be affected. We base our estimates on past

experience and other assumptions that we believe are reasonable under the circumstances, and we evaluate these estimates on an ongoing basis. We refer to accounting estimates of this type as critical accounting policies and estimates, which we discuss further below.

Use of estimates

In the opinion of management, the accompanying condensed consolidated balance sheets and related interim statements of operations, cash flows, and shareholders' deficits include all adjustments, consisting only of normal recurring items, necessary for their fair presentation in conformity with accounting principles generally accepted in the United States of America ("U.S. GAAP"). Preparing financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, and expenses. The significant estimates were made for the fair value of common stock issued for services, with notes payable arrangements in connection with note extension agreements, and as repayment for outstanding debts, in estimating the useful life used for depreciation and amortization of our long-lived assets, in the valuation of the derivative liability, and the valuation of deferred income tax assets. Actual results and outcomes may differ from management's estimates and assumptions.

Revenue recognition

The Company recognizes revenue from its technology licensing and commercialization activities in accordance with paragraph 605-10-S99-1 of the FASB Accounting Standards Codification for revenue recognition. The Company recognizes revenue when it is realized or realizable and earned.

The Company considers revenue realized or realizable and earned when all of the following criteria are met: (i) persuasive evidence of an arrangement exists, (ii) the services have been rendered to the customer and accepted by the customer as completed pursuant to Company's Licensing Agreements, (iii) collectability is reasonably assured. The Company has yet to realize any revenues from its licensing agreements.

Recently Issued Accounting Pronouncements

The Company is not aware of any recently issued accounting pronouncements that when adopted will have a material effect on the Company's financial position or result of its operations.

Results of Operations for the Three Months ended March 31, 2016 and March 31, 2015

	Three Months Ended March 31,		Favorable	
	2016	2015	(Unfavorable)	%
Revenue	\$ -	\$ 2,745	\$ (2,745)	-100.0%
Cost of revenue	-	824	824	100.0%
Gross profit	-	1,921	(1,921)	-100.0%
Operating expenses	1,402,120	433,554	(968,566)	223.4%
Loss from operations	(1,402,120)	(431,633)	(970,487)	224.8%
Other income (expense)	498,657	(48,522)	547,179	1115.0%
Net loss	\$ (903,463)	\$ (480,155)	\$ (423,308)	88.2%

Revenues

We had no revenue for the three months ended March 31, 2016 compared to \$2,745 for the three months ended March 31, 2015. We are in an early stage and our revenues will be small and null until a device or biological license receives FDA approval or international research licensing develops. The growth of our business is dependent on successfully raising additional capital to fund our growth.

Operating Expenses

Our operating expenses for the three months ended March 31, 2016 were approximately \$1,402,000 compared to \$434,000 for the corresponding period of the previous year. The operating expenses were comprised primarily from consulting and professional fees for the development of our intellectual property and expenses related to being a public company, approximately \$500,000 of which was paid for in stock issuances, and payment of another approximate \$400,000 of these fees were deferred.

Other Income (Expense)

Other income (expense) for the quarter ended March 31, 2016 was income of \$498,657 compared to expense of \$48,522 for the quarter ended March 31, 2015. This change was due primarily to a change in valuation of our derivative liabilities, which did not exist as of March 31, 2015, and interest expense resulting from the amortization of the discounts on notes payable, also which did not exist as of March 31, 2015. We anticipate continued large fluctuations in other income (expense) as a result of quarterly re-evaluation of these obligations.

Liquidity and Capital Resources

	As of		Increase
	<u>March 31,</u> <u>2016</u>	<u>December 31, 2015</u>	(Decrease)
Working Capital			
Current assets	\$ 246,313	\$ 377,706	\$ (131,393)
Current liabilities	8,999,726	9,486,153	486,427
Working capital deficit	<u>\$ (8,753,413)</u>	<u>\$ (9,108,447)</u>	<u>\$ 355,034</u>
Long-term debt	<u>\$ 287,662</u>	<u>\$ 199,270</u>	<u>\$ 88,392</u>
Stockholders' deficit	<u>\$ (9,013,376)</u>	<u>\$ (9,276,060)</u>	<u>\$ (262,684)</u>
	Three Months Ended March 31,		Increase
	<u>2016</u>	<u>2015</u>	(Decrease)
Statements of Cash Flows Select Information			
Net cash provided (used) by:			
Operating activities	\$ (426,056)	\$ (193,836)	\$ (232,220)
Investing activities	\$ -	\$ -	\$ -
Financing activities	\$ 493,476	\$ 218,496	\$ 274,980
	As of		Increase
	<u>March 31,</u> <u>2016</u>	<u>December 31, 2015</u>	(Decrease)
Balance Sheet Select Information			
Cash	<u>\$ 108,893</u>	<u>\$ 41,473</u>	<u>\$ 67,420</u>
Accounts payable and accrued expenses	<u>\$ 4,222,997</u>	<u>\$ 3,990,185</u>	<u>\$ 232,812</u>

Since inception and through March 31, 2016, the Company has raised approximately \$3.5 million in equity and debt transactions. These funds have been used to commence the operations of the Company to acquire and begin the development of its intellectual property portfolio. These activities include attending trade shows and corporate development. Our accompanying condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business for the twelve month period following the date of these condensed consolidated financial statements. The Company has incurred substantial losses since inception. Its current liabilities exceed its current assets and available cash is not sufficient to fund expected future operations. The Company is raising additional capital through debt and equity securities in order to continue the funding of its operations. However, there is no assurance that the Company can raise enough funds or generate sufficient revenues to pay its obligations as they become due, which raises substantial doubt about our ability to continue as a going concern. To reduce the risk of not being able to continue as a going concern, management is increasing the value of its intellectual property through regulatory approvals and obtaining additional patent rights and has initiated a private placement offering to

raise capital through the sale of its common stock. Although, uncertainty exists as to whether the Company will be able generate enough cash from operations to fund the Company's working capital needs or raise sufficient capital to meet the Company's obligations as they become due, no adjustments have been made to the carrying value of assets or liabilities as a result of this uncertainty. Our cash on hand at March 31, 2016 was approximately \$109,000. This will be insufficient to fund operations if additional capital is not raised. The Company raised an aggregate of approximately \$650,000 through the sale of equity and debt securities during the three months ended March 31, 2016.

The Company is not aware of any recently issued accounting pronouncements that when adopted will have a material effect on the Company's financial position or result of its operation.

Off-Balance Sheet Arrangements

We have no off-balance sheet arrangements.

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

We are a Smaller Reporting Company and are not required to provide the information under this item.

Item 4. Controls and Procedures.

Disclosure of controls and procedures.

We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our reports, filed under the Securities Exchange Act of 1934, is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms, and that such information is accumulated and communicated to our management, including our chief executive officer and chief financial officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable and not absolute assurance of achieving the desired control objectives. In reaching a reasonable level of assurance, management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. In addition, the design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, a control may become inadequate because of changes in conditions or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.

As required by the SEC Rule 13a-15(b), we carried out an evaluation under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this report. Based on the foregoing, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were not effective at the reasonable assurance level due to the material weaknesses described below.

In light of the material weaknesses described below, we performed additional analysis and other post-closing procedures to ensure our financial statements were prepared in accordance with generally accepted accounting principles. Accordingly, we believe that the financial statements included in this report fairly present, in all material respects, our financial condition, results of operations and cash flows for the periods presented.

A material weakness is a control deficiency (within the meaning of the Public Company Accounting Oversight Board (PCAOB) Auditing Standard No. 2) or combination of control deficiencies that result in more than a remote likelihood that a material misstatement of the annual or interim financial statements will not be prevented or detected. Management has identified the following two material weaknesses which have caused management to conclude that as of March 31, 2016 our disclosure controls and procedures were not effective at the reasonable assurance level:

1. We do not have written documentation of our internal control policies and procedures. Written documentation of key internal controls over financial reporting is a requirement of Section 404 of the Sarbanes-Oxley Act which is applicable to us for the quarter ended March 31, 2016. Management evaluated the impact of our failure to have written documentation of our internal controls and procedures on our assessment of our disclosure controls and procedures and has concluded that the control deficiency that resulted represented a material weakness.

2. We do not have sufficient segregation of duties within accounting functions, which is a basic internal control. Due to our size and nature, segregation of all conflicting duties may not always be possible and may not be economically feasible. However, to the extent possible, the initiation of transactions, the custody of assets and the recording of transactions should be performed by separate individuals. Management evaluated the impact of our failure to have segregation of duties on our assessment of our disclosure controls and procedures and has concluded that the control deficiency that resulted represented a material weakness.

To address these material weaknesses, management performed additional analyses and other procedures to ensure that the financial statements included herein fairly present, in all material respects, our financial position, results of operations and cash flows for the periods presented.

Changes in internal controls over financial reporting.

There has been no change in our internal control over financial reporting that occurred during the fiscal quarter covered by this Quarterly Report on Form 10-Q that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II - OTHER INFORMATION

Item 1. Legal Proceedings.

We are not currently involved in any litigation that we believe could have a material adverse effect on our financial condition or results of operations. There is no action, suit, proceeding, inquiry or investigation before or by any court, public board, government agency, self-regulatory organization or body pending or, to the knowledge of the executive officers of our company or any of our subsidiaries, threatened against or affecting our company, our common stock, any of our subsidiaries or of our companies or our subsidiaries' officers or directors in their capacities as such, in which an adverse decision could have a material adverse effect. Notwithstanding the foregoing, several lenders have commenced litigation against us which is in the early stages. We anticipate that these matters will be settled, however, if a settlement cannot be reached, we will vigorously defend these matters and we do not believe that there will be any material adverse effect as a result thereof, but there is always uncertainty in any litigation and a result cannot be guaranteed.

Item 1A. Risk Factors.

We are a Smaller Reporting Company (as defined in Rule 12b-2 of the Exchange Act) and are not required to provide the information under this item.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

Number of Common Shares Issued	Source of Payment	Amount
1,051,504	Services	\$ 492,806
70,110	Note extension	\$ 25,651
1,488,100	Cash	\$ 378,275
876,150	Conversion of notes	\$ 269,416

The above issuances of securities during the three months ended March 31, 2016 were exempt from registration pursuant to Section 4(2), and/or Regulation D promulgated under the Securities Act. These securities qualified for exemption under Section 4(2) of the Securities Act since the issuance securities by us did not involve a public offering. The offering was not a “public offering” as defined in Section 4(2) due to the insubstantial number of persons involved in the deal, size of the offering, manner of the offering and number of securities offered. We did not undertake an offering in which we sold a high number of securities to a high number of investors. In addition, these stockholders had the necessary investment intent as required by Section 4(2) since they agreed to and received share certificates bearing a legend stating that such securities are restricted pursuant to Rule 144 of the Securities Act. This restriction ensures that these securities would not be immediately redistributed into the market and therefore not be part of a “public offering.” Based on an analysis of the above factors, we have met the requirements to qualify for exemption under Section 4(2) of the Securities Act for this transaction.

Item 3. Defaults Upon Senior Securities.

None

Item 4. Mine Safety Disclosures.

Not applicable

Item 5. Other Information

None

Item 6. Exhibits

Exhibit Number	Exhibit Title
3.1	Certificate of Amendment to the Certificate of Incorporation affecting a 100 for one reverse stock split.
31.1	Certification of Principal Executive Officer and Principal Financial Officer, pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1	Certification of Principal Executive Officer and Principal Financial Officer, pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS *	XBRL Instance Document
101.SCH *	XBRL Taxonomy Schema
101.CAL *	XBRL Taxonomy Calculation Linkbase
101.DEF *	XBRL Taxonomy Definition Linkbase
101.LAB *	XBRL Taxonomy Label Linkbase
101.PRE *	XBRL Taxonomy Presentation Linkbase
In accordance with SEC Release 33-8238, Exhibit 32.1 and 32.2 are being furnished and not filed.	

* Furnished herewith. XBRL (Extensible Business Reporting Language) information is furnished and not filed or a part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, is deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and otherwise is not subject to liability under these sections.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: May 20, 2016

Endonovo Therapeutics, Inc.

By: /s/ Alan Collier
Alan Collier
Chief Executive Officer
(Duly Authorized Officer, Principal
Executive Officer and Principal
Financial Officer)

Certification of Principal Executive Officer and Principal Financial Officer
Pursuant to 18 U.S.C. 1350
(Section 302 of the Sarbanes-Oxley Act of 2002)

I, Alan Collier, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Endonovo Therapeutics, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 - (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - (c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 - (d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent functions):
 - (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 - (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal controls.

Dated: May 20, 2016

/s/ Alan Collier

Alan Collier
Chief Executive Officer and Principal Financial Officer

**CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the Quarterly Report of Endonovo Therapeutics, Inc. (the "Company") on Form 10-Q for the period ended March 31, 2016 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Alan Collier, Chief Executive Officer and Principal Financial Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

- (1) The Report on fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
- (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: May 20, 2016

/s/ Alan Collier
Chief Executive Officer , Interim Chief Financial
Officer, Secretary and Director
(Principal Executive, Financial and Accounting
Officer)

This certification accompanies each Report pursuant to § 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by the Sarbanes-Oxley Act of 2002, be deemed filed by the Company for purposes of §18 of the Securities Exchange Act of 1934, as amended.

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.